Computed tomography versus exercise testing in suspected coronary artery disease

Computed tomography versus exercise testing in suspected coronary artery disease - CRESCENT trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34065

Enrollment

1250

Registered

2011-01-03

Start date

2011-04-13

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Diagnostic intervention with replacement of the stress test by a cardiac CT scan (in the absence of contra-indications)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Stable symptoms of hest pain/dyscomfort or dyspnea that is possibly the result of coronary artery disease. Age >18 yrs, ability and willingness to provide infromed consent

Exclusion criteria

Exclusion criteria: A history of surgical or percutaneous coronary revascularization, or non-revascularized angiographic obstructive coronary artery disease (>50% diameter reduction). Normal invasive coronary angiography or stress imaging less than 1 years ago.

Design outcomes

Primary

Measure	Time frame
a) Absence of chest pain at 1 year b) Diagnostic yield of high-risk coronary artery disease	—

Secondary

Measure	Time frame
Absence of chest pain at 3 and 5 years Quality of life at 1, 3, 5 years Time and cost until diagnosis Proportion of invasive catheterizations followed by a revascularization procedure Overall costs: diagnostics, therapy at 1, 3, 5 years. Cost-effectiveness (including non-medical costs, including those related to lost productivity) Event-free survival, composite endpoint: death, myocardial infarction, CVA, UAP, ED visits, late revascularizations. Radiation exposure	—

Measure

Time frame

Absence of chest pain at 3 and 5 years Quality of life at 1, 3, 5 years Time and cost until diagnosis Proportion of invasive catheterizations followed by a revascularization procedure Overall costs: diagnostics, therapy at 1, 3, 5 years. Cost-effectiveness (including non-medical costs, including those related to lost productivity) Event-free survival, composite endpoint: death, myocardial infarction, CVA, UAP, ED visits, late revascularizations. Radiation exposure

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)